References:
- Semaglutide shows promise as a potential alcohol use disorder medication - (https://www.niaaa.nih.gov/news-events/research-update/semaglutide-shows-promise-potential-alcohol-use-disorder-medication)
- Update on FDA’s ongoing evaluation of reports of suicidal thoughts or actions in patients taking a certain type of medicines approved for type 2 diabetes and obesity - (https://www.fda.gov/drugs/drug-safety-and-availability/update-fdas-ongoing-evaluation-reports-suicidal-thoughts-or-actions-patients-taking-certain-type)
- The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission - (https://insight.jci.org/articles/view/170671#B1)
- Alcohol - (https://www.who.int/news-room/fact-sheets/detail/alcohol)
- Alcohol drinking cut in half with diabetes medication - (https://www.gu.se/en/news/alcohol-drinking-cut-in-half-with-diabetes-medication-0)
- Semaglutide (Oral Route) - (https://www.mayoclinic.org/drugs-supplements/semaglutide-oral-route/side-effects/drg-20492085)
Editor: Dr. Krishanga
Technically Checked by: Lingaraj
